Medpace Faces Class Action Lawsuit for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MEDP?
Source: Globenewswire
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud related to the misrepresentation of the book-to-bill ratio, which led to a 15.9% stock drop on February 9, 2026, highlighting serious investor concerns about financial transparency.
- Stock Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, indicating a significant loss of market confidence in the company's financial health, which could adversely affect investor trust moving forward.
- Ongoing Issues: BFA is investigating reports of increasing cancellation rates and a declining book-to-bill ratio down to 0.88, which may lead to further investor losses and exacerbate doubts about the company's future performance.
- Executive Changes: Medpace's President Jesse Geiger announced his resignation, which could impact the company's leadership and strategic direction, prompting investors to monitor how this change might affect governance and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 421.370
Low
462.00
Averages
569.17
High
660.00
Current: 421.370
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud related to the misrepresentation of the book-to-bill ratio, which led to a 15.9% stock drop on February 9, 2026, highlighting serious investor concerns about financial transparency.
- Stock Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, indicating a significant loss of market confidence in the company's financial health, which could adversely affect investor trust moving forward.
- Ongoing Issues: BFA is investigating reports of increasing cancellation rates and a declining book-to-bill ratio down to 0.88, which may lead to further investor losses and exacerbate doubts about the company's future performance.
- Executive Changes: Medpace's President Jesse Geiger announced his resignation, which could impact the company's leadership and strategic direction, prompting investors to monitor how this change might affect governance and market performance.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Medpace, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, which could expose the company to significant legal risks.
- Stock Price Plunge: Following the release of its Q4 2025 earnings on February 9, 2026, which revealed a book-to-bill ratio of 1.04, significantly below guidance, Medpace's stock price fell by 15.9% to close at $446.05, indicating market concerns about the company's outlook.
- Investor Action Deadline: Investors are advised to apply by June 8, 2026, to be appointed as Lead Plaintiff in the class action, highlighting the potential impact on a large number of investors and increasing the company's exposure to potential damages.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in securities class actions, founded over 85 years ago, and is known for advocating for victims of securities fraud, suggesting that this case may attract significant attention and have broader implications.
See More
Medpace Holdings Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiff by June 8, 2026, to participate in the class action without incurring any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and was ranked No. 1 by ISS Securities Class Action Services in 2017, recovering over $438 million for investors in 2019 alone, showcasing its strong track record in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the litigation process.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace Holdings, Inc. on behalf of investors who purchased shares between April 22, 2025, and February 9, 2026, alleging that the company made false and misleading statements that artificially inflated its stock price during this period.
- Investor Losses: The complaint indicates that Medpace's misrepresentations became apparent through poor performance throughout the class period, leading to significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- Legal Process: Investors must apply by June 5, 2026, to be appointed as lead plaintiffs, underscoring the urgency of the case and the need to protect investor rights, reflecting the legal system's commitment to safeguarding shareholder interests.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities and commercial litigation, demonstrating its expertise and broad influence in protecting investor rights.
See More
Medpace Faces Securities Class Action Amid Declining Stock
- Significant Stock Drop: Medpace's stock plummeted by $84.30, a decline of over 15.9%, after revealing a Q4 book-to-bill ratio of only 1.04x on February 9, 2026, which starkly contrasted with the projected 1.15x, severely undermining investor confidence.
- Concealment of Internal Data: The lawsuit alleges that Medpace's leadership had access to critical internal data regarding backlog cancellation trends and therapeutic area concentration throughout the class period, yet publicly portrayed a misleadingly strong business performance, potentially leading investors to make ill-informed decisions.
- Undisclosed Risk Signals: Despite acknowledging high cancellation rates in April 2025, management maintained the 1.15x target, indicating a disregard for potential risks, which could result in future performance shortfalls and further stock declines.
- Class Action Deadline: The lead plaintiff deadline for the securities class action is June 8, 2026, requiring investors to submit claims by this date to seek recovery of losses, highlighting concerns over the company's transparency and governance practices.
See More
Multiple Companies Facing Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is facing a class action lawsuit for the period from February 7, 2025, to February 12, 2026, due to failure to disclose risks of declining advertising revenues, which is expected to negatively impact its stock price, with investors needing to file a lead plaintiff motion by May 29, 2026.
- New Era Energy Violations: New Era Energy & Digital, Inc. is accused of overstating progress on its Texas data center project and engaging in fraudulent schemes from November 6, 2024, to December 29, 2025, which could distort financial results, requiring investor action by June 1, 2026.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. faces legal issues due to its Phase 3 clinical trial failing to meet primary endpoints from June 16, 2025, to February 20, 2026, potentially affecting future funding capabilities, with a lead plaintiff motion deadline of June 1, 2026.
- Medpace Holdings Misleading Performance: Medpace Holdings, Inc. is accused of exaggerating its book-to-bill ratio for Q4 2025 from April 22, 2025, to February 9, 2026, which may lead to investor misunderstandings about the company's prospects, with a lead plaintiff motion deadline of June 8, 2026.
See More
Medpace Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud related to the misrepresentation of the book-to-bill ratio, which led to a 15.9% stock drop on February 9, 2026, highlighting serious investor concerns about financial transparency.
- Stock Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, indicating a significant loss of market confidence in the company's financial health, which could adversely affect investor trust moving forward.
- Ongoing Issues: BFA is investigating reports of increasing cancellation rates and a declining book-to-bill ratio down to 0.88, which may lead to further investor losses and exacerbate doubts about the company's future performance.
- Executive Changes: Medpace's President Jesse Geiger announced his resignation, which could impact the company's leadership and strategic direction, prompting investors to monitor how this change might affect governance and market performance.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Medpace, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, which could expose the company to significant legal risks.
- Stock Price Plunge: Following the release of its Q4 2025 earnings on February 9, 2026, which revealed a book-to-bill ratio of 1.04, significantly below guidance, Medpace's stock price fell by 15.9% to close at $446.05, indicating market concerns about the company's outlook.
- Investor Action Deadline: Investors are advised to apply by June 8, 2026, to be appointed as Lead Plaintiff in the class action, highlighting the potential impact on a large number of investors and increasing the company's exposure to potential damages.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in securities class actions, founded over 85 years ago, and is known for advocating for victims of securities fraud, suggesting that this case may attract significant attention and have broader implications.
See More
Medpace Holdings Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiff by June 8, 2026, to participate in the class action without incurring any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and was ranked No. 1 by ISS Securities Class Action Services in 2017, recovering over $438 million for investors in 2019 alone, showcasing its strong track record in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the litigation process.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace Holdings, Inc. on behalf of investors who purchased shares between April 22, 2025, and February 9, 2026, alleging that the company made false and misleading statements that artificially inflated its stock price during this period.
- Investor Losses: The complaint indicates that Medpace's misrepresentations became apparent through poor performance throughout the class period, leading to significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- Legal Process: Investors must apply by June 5, 2026, to be appointed as lead plaintiffs, underscoring the urgency of the case and the need to protect investor rights, reflecting the legal system's commitment to safeguarding shareholder interests.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities and commercial litigation, demonstrating its expertise and broad influence in protecting investor rights.
See More
Medpace Faces Securities Class Action Amid Declining Stock
- Significant Stock Drop: Medpace's stock plummeted by $84.30, a decline of over 15.9%, after revealing a Q4 book-to-bill ratio of only 1.04x on February 9, 2026, which starkly contrasted with the projected 1.15x, severely undermining investor confidence.
- Concealment of Internal Data: The lawsuit alleges that Medpace's leadership had access to critical internal data regarding backlog cancellation trends and therapeutic area concentration throughout the class period, yet publicly portrayed a misleadingly strong business performance, potentially leading investors to make ill-informed decisions.
- Undisclosed Risk Signals: Despite acknowledging high cancellation rates in April 2025, management maintained the 1.15x target, indicating a disregard for potential risks, which could result in future performance shortfalls and further stock declines.
- Class Action Deadline: The lead plaintiff deadline for the securities class action is June 8, 2026, requiring investors to submit claims by this date to seek recovery of losses, highlighting concerns over the company's transparency and governance practices.
See More
Multiple Companies Facing Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is facing a class action lawsuit for the period from February 7, 2025, to February 12, 2026, due to failure to disclose risks of declining advertising revenues, which is expected to negatively impact its stock price, with investors needing to file a lead plaintiff motion by May 29, 2026.
- New Era Energy Violations: New Era Energy & Digital, Inc. is accused of overstating progress on its Texas data center project and engaging in fraudulent schemes from November 6, 2024, to December 29, 2025, which could distort financial results, requiring investor action by June 1, 2026.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. faces legal issues due to its Phase 3 clinical trial failing to meet primary endpoints from June 16, 2025, to February 20, 2026, potentially affecting future funding capabilities, with a lead plaintiff motion deadline of June 1, 2026.
- Medpace Holdings Misleading Performance: Medpace Holdings, Inc. is accused of exaggerating its book-to-bill ratio for Q4 2025 from April 22, 2025, to February 9, 2026, which may lead to investor misunderstandings about the company's prospects, with a lead plaintiff motion deadline of June 8, 2026.
See More
